Valente Ana, Teixeira Tavares Nuno, Caeiro Cláudia, Barbosa Miguel, Augusto Isabel
Medical Oncology, Centro Hospitalar e Universitário de São João, Porto, PRT.
Cureus. 2023 Feb 12;15(2):e34893. doi: 10.7759/cureus.34893. eCollection 2023 Feb.
A small but important subset of patients with metastatic breast cancer has an oligometastatic disease. Some of these patients are highly responsive to systemic therapy and have the potential to achieve complete remission with treatment. However, it remains to be clarified the best locoregional and systemic treatment strategy for such patients and what features can determine whose patients are the best candidates. We also don't know what will be the role of cyclin-dependent kinase 4/6 inhibitors in those cases. We report the case of a 41-year-old woman with HR-positive/HER2-negative oligometastatic breast cancer who, after an excellent response to systemic treatment with palbociclib, anastrozole, and goserelin, underwent breast surgery and liver metastasectomy. After completing three years of systemic treatment, the CDK inhibitor was discontinued, maintaining the hormone therapy. The patient remained under regular follow-up with no evidence of disease after eight months.
一小部分但很重要的转移性乳腺癌患者患有寡转移疾病。其中一些患者对全身治疗高度敏感，有可能通过治疗实现完全缓解。然而，对于这类患者，最佳的局部区域和全身治疗策略以及哪些特征可以确定哪些患者是最佳候选者仍有待阐明。我们也不知道细胞周期蛋白依赖性激酶4/6抑制剂在这些病例中的作用会是什么。我们报告了一例41岁HR阳性/HER2阴性寡转移乳腺癌女性患者的病例，该患者在用哌柏西利、阿那曲唑和戈舍瑞林进行全身治疗后反应良好，随后接受了乳房手术和肝转移灶切除术。在完成三年的全身治疗后，停用了CDK抑制剂，继续维持激素治疗。八个月后，患者仍在定期随访中，无疾病证据。
